What is Novocuff?
Novocuff, Inc. operates at the intersection of medical device engineering and maternal health, specifically targeting the prevention of preterm births. The company's core technology is engineered to address complex obstetric challenges, including cervical shortening and preterm premature rupture of membranes (PPROM). By providing a mechanical intervention that aims to stabilize the cervix, Novocuff seeks to extend gestation periods, thereby significantly improving health outcomes for both mothers and infants.
In a market landscape where women's health technology is increasingly recognized as a critical sector for innovation, Novocuff distinguishes itself through a focus on evidence-based clinical solutions. The company's market position is bolstered by its commitment to addressing historically underserved areas of obstetrics, leveraging specialized engineering to solve high-stakes medical problems that have long lacked effective, non-invasive interventions.
How much funding has Novocuff raised?
Novocuff has raised a total of $52M across 2 funding rounds:
Series A
$26M
Series A
$26M
Series A (2024): $26M with participation from AXA IM ALTS - Real Assets, RH Capital, and Avestria Ventures Management
Series A (2024): $26M led by Avestria Ventures Management, AXA IM ALTS - Real Assets, and RH Capital
Key Investors in Novocuff
AXA IM ALTS - Real Assets
AXA IM Alts is a global leader in alternative investments, managing a vast portfolio that includes infrastructure and impact-focused assets, with a strong commitment to sustainable financial growth.
RH Capital
RH Capital is an impact-first venture fund dedicated to catalyzing innovation in women's health, focusing on maternal health, fertility, and pelvic health to improve health equity.
Avestria Ventures Management
Avestria Ventures is a California-based firm specializing in early-stage women's health and life science companies, supporting female-led ventures that utilize technology to enhance healthcare access.
What's next for Novocuff?
With the successful closure of this Series A financing, Novocuff is poised to enter a period of accelerated growth and clinical validation. The strategic roadmap likely includes expanding clinical trial footprints, refining manufacturing processes to meet regulatory standards, and preparing for commercial market entry. The involvement of impact-focused investors suggests a long-term commitment to scaling the technology while maintaining a focus on health equity and accessibility.
Moving forward, the company will likely prioritize the integration of its devices into standard obstetric care protocols. By leveraging the expertise of its investor base, Novocuff is set to navigate the complex regulatory and reimbursement landscapes inherent in the medical device industry, ultimately aiming to establish its platform as a standard of care for high-risk pregnancies.
